novo nordisk glp-1 receptor agonist weight management diabetes treatments to launch Ozempic for type 2 in US In the original clinical trials

A secondary analysis of clinical trial data found that up to 40% of weight lost on semaglutide can be lean mass -- muscle and bone -- rather than fat, particularly in women and older adults

Kidney Int 2018

In addition, BCBSM will change prior authorization requirements in this space on Saxenda, Wegovy and Zepbound beginning Aug

A health warning on repurposed drugs None of the above should be read to suggest and it is not DW's recommendation that anyone use GLP-1 agonists, or any other drug, to treat any "off label"/non-approved condition, without personal, professional medical advice

Finding proper GLP-1 side effects relief here requires choosing a pure osmotic option rather than falling into traditional fiber traps

Could we discuss this within those guidelines?" Option two: request a referral